⚠️ Serious warning: Nothing on this website is approved by any physician. Doz is only a tool to help physicians and to search drugs easily. Taking medicines without medical supervision can be fatal.

Fondaparinux

فونداپارینوکس

⚠ Unverified

🩸 Blood And Blood Forming OrgansIndirect factor Xa inhibitor

🤰 Pregnancy:Use with caution 🤱 Breastfeeding:Use with caution 👶 Children:Use with caution 👴 Older adults:Use with caution 🇮🇷 Not found in Iran list ⛔ 1 contraindications 🇺🇸 FDA authorized generic NDA021345 ATC B01AX05

Market / country: 🇺🇸 USA

Arixtra (US)

🧮 Dose calculator

Disease / regimen

Venous thromboembolism prophylaxis (medical or surgical) · Regimen source: FDA Fondaparinux · 2.2 FDA Fondaparinux · 2.3

• First dose 6–8 h after surgery once haemostasis is established (earlier increases bleeding). Hip fracture: up to 24 additional days. FDA Fondaparinux · 2.2

Formulation

Age *

Weight (kg) *

Enter age and weight.

🛡️ Safety & information

Contraindications

⛔ CrCl <30; active major bleeding; bacterial endocarditis; thrombocytopenia with a positive anti-platelet antibody test in the presence of fondaparinux; body weight <50 kg for prophylaxis; hypersensitivity. FDA Fondaparinux · 4

Warnings

• Boxed warning: spinal or epidural haematoma with neuraxial anaesthesia or puncture (long-term or permanent paralysis). FDA Fondaparinux · Boxed Warning

Formulations

2.5 mg/0.5 mL prefilled syringe — injection 🇺🇸 USA FDA Fondaparinux · 3
7.5 mg/0.6 mL prefilled syringe (also 5 mg/0.4 mL, 10 mg/0.8 mL) — injection 🇺🇸 USA FDA Fondaparinux · 3

👥 Special populations

🤰 PregnancyUse with caution
Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Fondaparinux · 8.1
“Risk Summary Available data from published literature and postmarketing reports have not reported a clear association with fondaparinux sodium and adverse developmental outcomes.”
🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Fondaparinux · 8.2
“Risk Summary There are no data on the presence of fondaparinux sodium in human milk, or the effects on milk production.”
👶 ChildrenUse with caution
The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Fondaparinux · 8.4
“The safety and effectiveness of fondaparinux sodium for the treatment of venous thromboembolism have been established in pediatric patients aged 1 year and older weighing at least 10 kg.”
👴 Older adultsUse with caution
Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Fondaparinux · 8.5
“When using fondaparinux sodium in elderly patients, pay particular attention to dosing directions and concomitant medications (especially anti-platelet medication) [see Warnings and Precautions (5.2) ] .”
⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.

🔗 Reference links

FDA (approval record)NDA021345
DailyMed (FDA label)FDA Fondaparinux
MedlinePlus (NIH)Fondaparinux Injection
WHO ATC/DDDB01AX05
Darooyab (Iran)Fondaparinux

🇮🇷 Not found in Iran list Darooyab · G-1688/Fondaparinux

Darooyab lists no registered dosage form or brand for this drug. This does not prove it is unavailable.

📚 Reference status for this drug

Shows which sources have references recorded for this drug and which do not.

FDA label (DailyMed)✅ Present
FDA Fondaparinux · 3 FDA Fondaparinux · 2.2 FDA Fondaparinux · 2.3 FDA Fondaparinux · 2.4 FDA Fondaparinux · 4 FDA Fondaparinux · Boxed Warning FDA Fondaparinux · SPL approval / marketing category FDA Fondaparinux · 8.1 FDA Fondaparinux · 8.2 FDA Fondaparinux · 8.4 FDA Fondaparinux · 8.5
UK SmPC (eMC / MHRA)❌ Not present
Published guideline❌ Not present
Licensed reference (medical school)❌ Not present
Iranian leaflet (IFDA)❌ Not present
Pharmacy website (secondary, unreliable)✅ Present
Darooyab · G-1688/Fondaparinux
Clinical review⚠ Unverified

🔗 Similar drugs

For the same diseases

Apixaban Dabigatran Edoxaban Enoxaparin Heparin Rivaroxaban